Palm Beach Gardens Medical Center Earns Blue Distinction® Center+ Designation for Quality and Cost-Efficiency in Knee and Hip Replacement Surgeries

Blue Cross and Blue Shield Association [BCBSA] selects Palm Beach Gardens Medical Center as a Blue Distinction Center+ for Knee and Hip Replacement, part of the Blue Distinction Specialty Care program.

Blue Distinction Centers are nationally designated healthcare facilities that show a commitment to delivering high-quality patient safety and better health outcomes, based on objective measures that were developed with input from the medical community and leading accreditation and quality organizations.

“Palm Beach Gardens Medical Center is proud to be recognized by BCBSA for meeting the robust selection criteria for knee and hip replacements set by the Blue Distinction Specialty Care program”, said Teresa Urquhart, chief executive officer for Palm Beach Gardens Medical Center. “This designation is a testament to the hard work and dedication our orthopedic medical staff provides to each patient who is treated at our hospital. We could not be more grateful for this accomplishment.”

Facilities designated as Blue Distinction Centers® for Knee and Hip Replacement demonstrate expertise in total knee and total hip replacement surgeries, resulting in fewer patient complications and hospital readmissions. Designated facilities include hospitals (with and without an onsite Intensive Care Unit) and Ambulatory Surgery Centers (ASC).

All designated facilities must maintain national accreditation, and ASCs are also required to have an advanced orthopedic certification. In addition to meeting these quality thresholds, hospitals designated as Blue Distinction Centers+ are on average 20 percent more cost-efficient in an episode of care compared to other facilities. Quality is key: only those facilities that first meet nationally established, objective quality measures will be considered for designation as a Blue Distinction Center+.

For more information about our orthopedics program and services, go to www.pbgmc.com/services/orthopedics or call 561-622-1411.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”